Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Meet the Editorial Advisory Board of The AAPS Journal: N-Z

Meet the Editorial Advisory Board of The AAPS Journal: N-Z

Vincent Hon-Leung Lee 

Vincent H.L. Lee is a research professor at the School of Pharmacy, Chinese University of Hong Kong. Prior to that, he was associate director at the Office of Pharmaceutical Science, Food and Drug Administration; vice president of Biological, Formulation, and Material Science at ALZA; and Gavin S. Herbert Professor of Pharmaceutical Sciences, professor of ophthalmology, chairman of the Department of Pharmaceutical Sciences and associate dean for Research and Graduate Affairs at the University of Southern California.
Lee is a world-renowned leader in drug delivery. His research was funded by the National Institutes of Health (NIH) in the United States for more than 20 years, a record that has placed him among the top five percent of all the NIH grant applicants. He has published more than 200 papers in three inter-related areas, including: (a) defining the biochemical barriers to peptide and protein drug delivery; (b) elucidating the structure-function of drug transporters; and (c) characterizing the pharmacokinetic barriers to drug delivery in treating retinal degenerative diseases. Over 30 graduate students, postdoctoral fellows, and visiting scientists from North America, Asia, and Europe have been trained by Lee.
Several international honors and awards, including the Young Investigator Award of the Controlled Release Society, Research Achievement Award in Pharmaceutics and Drug Delivery of the American Association of Pharmaceutical Scientists (AAPS), and Pharmaceutical Scientist of the Year award of the FIP Board of Pharmaceutical Sciences, have recognized Lee's research accomplishments. In 2002, he was awarded a Citation of Merit by the University of Wisconsin School of Pharmacy (only an honorary degree constitutes a higher honor than a citation). In 2003, he was awarded an Honorary Doctor of Science degree from the University of London, United Kingdom.
Lee was elected president of AAPS in 1996 and the Controlled Release Society in 1993. He is a member of several editorial advisory boards and scientific advisory boards and was editor-in-chief of Pharmaceutical Research and Advanced Drug Delivery Reviews.

Juliane Nguyen, Ph.D., early career member 

P_A67933_Juliane Nguyen_picture_95x120pxpx
Juliane Nguyen, Ph.D., is an associate professor of Pharmaceutical Sciences at the University at Buffalo. Her lab develops novel protein-, RNA-, and lipid-based biochemical and delivery platforms for treating myocardial infarction and cancer. Dr. Nguyen’s research has been recognized through the Biomedical Breakthrough Award (2011), the University at Buffalo - Exceptional Scholar Young Investigator Award (2017), and the NSF CAREER Award (2018). She received her PharmD and her Ph.D. in Pharmaceutical Sciences from the Philipps-University of Marburg (Germany), where she was mentored by Dr. Thomas Kissel. She then trained at UCSF under Dr. Frank Szoka, where she was a Deutsche Forschungsgemeinschaft Postdoctoral Fellow.

K.Sandy Pang, Ph.D 

Pang, Editor
K.Sandy Pang, Ph.D., received her B.Sc. (Pharmacy) from the University of Toronto and Ph.D. (Pharm Chem) from USCF at San Francisco, and was a Fogarty fellow at the National Institutes of Health. She is presently Professor of Pharmacy and Pharmacology at the Faculties of Pharmacy and Medicine at the University of Toronto.
Dr. Pang is known for her contributions to the fields of pharmacokinetics, drug metabolism, and liver physiology. Her research is aimed towards a mechanistic-based understanding of the handling of drugs and their metabolites within eliminating organs, namely the liver, the intestine, and kidney. Her approach is via the development and formulation of physiologically relevant processes of organ clearances through theoretical treatises and the validation by experimental approaches in vitro [expression systems, cells and subcellular preparations] and in perfused organs.
The principles learnt on hepatic clearance have been extended to examine heterogeneity in intestinal absorption and clearance. Her work on metabolite kinetics emphasizes the need for consideration of heterogeneity and the order of sequential processing and led to the finding that differences exist in the kinetics of formed vs. preformed metabolites. This area sheds insight to metabolite-mediated toxicities. These important concepts developed by Dr. Pang on drug and metabolite clearances have provided a solid basis towards the understanding of metabolism, transport, and removal of drugs and metabolites in eliminating organs such as the liver, intestine, and kidney.
Her more recent interests include the role of the vitamin D receptor on regulation of transporter and enzymes and other nuclear receptors and on siRNA hepatic disposition.
She was the recipient of the NIH Research Career Development Award, Faculty Development award from the Medical Research Council of Canada, the McNeil Award from the Faculties of Pharmacies in Canada, and the Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism from the American Association of Pharmaceutical Scientists (AAPS).

Murali Ramanathan, Ph.D. 

Ramanathan, Editor
Dr. Murali Ramanathan is an Associate Professor of Pharmaceutical Sciences and Neurology at the State University of New York at Buffalo.
His research interest include the treatment of multiple sclerosis, pharmaceutical applications of genomics and pharmacogenomic modeling.
Dr. Ramanathan received his Ph.D. in Bioengineering from the University of California at San Francisco. He has a M.S. in Chemical Engineering from Iowa State University, Ames IA and a B.Tech (Honors) from the Indian Institute of Technology, Kharagpur, India.

Christos Reppas - Professor of Pharmaceutics 

P_A37535_Reppas photo_95x120px
Christos Reppas is Professor of Pharmaceutics, Department of Pharmacy, National and Kapodistrian University of Athens (NKUA), Greece. He received his B. Pharm degree in Pharmacy from NKUA in 1982 and his Ph.D in 1986 from the same University. From 1988 to 1989 he completed a postdoctoral fellowship in Pharmaceutics at the University of Michigan (USA) and then he joined NKUA in 1989 as a Lecturer. He has held research positions with the University of London (UK), the University of Michigan (USA), Glaxo R and D (UK) and the University of Frankfurt (Germany). Research interests focus on the effects of gastrointestinal physiology on intraluminal performance of xenobiotics and the development of in vitro tests that are predictive of the intraluminal dosage form and drug performance. He is coauthor of more than 100 peer reviewed papers in international journals, two books and one patent.

Wolfgang Sadée, Dr.rer.nat. 

Sadee, Editor
Dr. Sadée is Felts Mercer Professor of Medicine and Pharmacology, Chair, Department of Pharmacology, and Director, Program in Pharmacogenomics, College of Medicine, The Ohio State University, Columbus OH. At OSU, he holds joint appointments in Pharmacy, Psychiatry, Medical Genetics, and is member of the Comprehensive Cancer Center and the Heart & Lung Research Institute.
He studied Pharmacy and received his doctorate in Pharmaceutical Chemistry at the FU Berlin in 1968. After two post-doctoral positions at UCSF and the FU Berlin, he joined USC in Los Angeles as Assistant Professor of Pharmacy and Medicine from 81-83, and subsequently, moved to UCSF, serving as Professor of Biopharmaceutical Sciences and Pharmaceutical Chemistry, University of California San Francisco until 2002.
Dr. Sadée’s research focuses the genetic basis of variable drug response in CNS and cardiovascular diseases, including addiction, and in cancer chemotherapy. He also pursues drug discovery in the treatment of addiction.
Dr. Sadée has published over 300 research papers and monographs. He has received the first AAPS Research Achievement Award in Biotechnology, the Paul Dawson Award in Biotechnology from AACP, and the 2001 Distinguished Pharmaceutical Scientist Award from AAPS.
He has served as founding editor of Pharmaceutical Research and the open access, on-line AAPS Journal. He teaches pharmacogenomics, pharmacology, and history of health sciences.

Danny D. Shen, Ph.D. 

Shen, DD, Editor
Danny Shen received his doctoral degree in pharmaceutics from the State University of New York at Buffalo in 1975. He is currently Professor and Chair of Pharmacy and Professor of Pharmaceutics at the University of Washington. He also holds a Member appointment in the Clinical Research Division at the Fred Hutchinson Cancer Research Center. Prior to his joining the faculty at the University of Washington in 1984, he held faculty appointments at the University of Kansas Medical Center (1975-1979) and State University of New York at Buffalo (1979-1984).
Dr. Shen is a Fellow of the AAPS, and a member of several other scientific societies, including the American Society of Pharmacology and Experimental Therapeutics (ASPET) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT). He is a member of the editorial advisory board for AAPS Journal, Pharmaceutical Research, and Journal of Pharmaceutical Sciences. He has served as advisor or consultant to governmental agencies (e.g., National Institutes of Health, Food and Drug Administration) and drug companies.
Dr. Shen has a broad range of research interests involving drug metabolism, drug transport in the CNS, and pharmacokinetics-pharmacodynamics of opioid analgesics. He has published over 160 journal articles, reviews and book chapters.

Steven J. Shire, Ph.D. 

Shire, Editor
Dr. Shire received his Ph.D. from Indiana University Chemistry Department and, after Post Doctoral Training at the University of Connecticut, began his career at Genentech as Research Scientist in the Department of Protein Chemistry.
He was involved in the early work to isolate heterologous recombinant proteins expressed in bacterial systems. This work led to the granting of a patent and served as the basis for further product development of proteins expressed in bacterial systems. During his tenure in the Protein Chemistry Department he used numerous physicochemical techniques to characterize Genentech proteins at various stages of development.
Shortly after the creation of the Pharmaceutical Research and Development Department at Genentech, he joined the department where he made numerous contributions to development of protein formulation and delivery. In addition, he set up one of the first analytical ultracentrifugation laboratories in the Biotechnology industry.
Currently he is a Staff Scientist and Group Leader in the Late Stage Pharmaceutical and Device Development Department at Genentech, and an adjunct faculty member of the USC School of Pharmacy and University of Connecticut School of Pharmaceutical Sciences. He has been responsible for directing research and development of formulations for a variety of recombinant human proteins including Pulmozyme® and Xolair®.
Dr. Shire has served as the chair of the American Association of Pharmaceutical Scientists (AAPS) Biotechnology Section, and was elected as a Fellow of AAPS in 1998 and member at large to the AAPS Executive Council in 2001. He has published over 50 reviews and papers dealing with various aspects of formulation and pharmaceutical development of therapeutic proteins.

Duxin Sun, PhD.  

Duxin Sun
Duxin Sun, Ph.D., is a professor in the Department of Pharmaceutical Sciences and William I. Higuchi Collegiate Professor in the College of Pharmacy at the University of Michigan. Sun serves as the director of Pharmacokinetics (PK) Core. He also has joint appointment in the Chemical Biology program, the Interdisciplinary Medicinal Chemistry program, and University of Michigan’s Comprehensive Cancer Center.
Sun’s research interests focus on drug discovery to inhibit cancer stem cells and nanomedicine for cancer therapeutics and imaging. His research has made significant contributions to develop small molecules to inhibit novel cancer stem cell targets to prevent tumor formation and metastasis. He also developed a nanotheranostics, which incorporates therapeutic agent and imaging probe into one nanoparticle, for cancer therapy and tumor imaging. His group is also interested in direct measurement and computation modeling of drug dissolution in the human GI tract to ensure bioequivalence and product quality for modified release and locally acting drugs.
Sun has published more than 130 papers, 85 meeting abstracts, 9 book chapters, and holds 12 U.S. patents. He has supervised 27 Ph.D. students and 40 postdoctoral fellows and visiting scientists. Sun has served as chair of the PPB (Physical Pharmacy and Biopharmaceutics) section of AAPS (American Association of Pharmaceutical Scientists) and as vice president of the American Chinese Pharmaceutical Association (ACPA). Sun has served on study sections for the NIH, FDA, Cancer Research UK, French National Research Agency, and Italian Ministry of Health.

Jashvant (Jash) Unadkat, Ph.D 

Unadkat, Editor
Jashvant (Jash) Unadkat, Ph.D. is a Professor of Pharmaceutics in the School of Pharmacy at the University of Washington, Seattle.
He received his Bachelors degree in Pharmacy (B.Pharm.) from the University of London (1977), his Ph.D. from the University of Manchester (1982) and his postdoctoral training at the University of California at San Francisco (1982-85).
Dr. Unadkat’s research interests are focused on elucidating the mechanisms of transport and metabolism of anti-AIDS and anti-cancer drugs. In particular his laboratory has been interested in metabolism and transport of drugs during pregnancy, transport of drugs across the placental, intestinal and blood-brain barrier and in vitro to in vivo correlation of drug interactions.
Dr. Unadkat has published more than 100 research papers. Dr. Unadkat is a fellow of AAPS and the founding member and co-chair (1999-2001) of the focus group of AAPS on Drug Transport and Uptake. Dr. Unadkat has been an Associate Editor for the Journal of Pharmaceutical Sciences, an Editor of The AAPS Journal., and a member of the NIH Pharmacology study section (2000-3). Dr. Unadkat is currently on the editorial board of J. Pharm. Sci and The AAPS Journal.
Dr. Unadkat has organized or co-organized various national and international conferences including the 1st AAPS Workshop on Drug Transport, Georgia, 2003, the AAPS Workshop on Pharmacokinetics and Pharmacodynamics of Drugs in Pregnant and Lactating Women: Issues and Challenges, Crystal City, 2004, the EUFEPS conference on Drug Transporters: Integrative Approaches in ADME Research, Copenhagen, 2004 & 2006, and the AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside, Parsippany, 2005, and conferences on The Biomedical Transporters, Switzerland, 2005 & 2007.

M. Guillaume Wientjes 

Wientjes, Guill, Editor
M. Guillaume Wientjes received his training in pharmaceutics at the University of Leyden, UCSF and the University at Buffalo, where he received his Ph.D. with Dr. Gerhard Levy.
He then moved to Columbus, Ohio, where he did postdoctoral training and rose through the ranks to his current position of professor of pharmacy at The Ohio State University.
He is recognized for his use of computational modeling and simulation in cancer chemotherapy. He has demonstrated the value of this approach in a number of areas, including the pharmacokinetics/pharmacodynamics of regional therapy, mechanisms of chemoresistance, and development of mathematical models to guide therapy selection.
His studies with regional therapy have established that the kinetics of drug distribution on organ and sub-organ levels are determined by cell density, cell type, and tissue architecture. The new understanding of regional drug distribution was used to design an improved treatment schedule for the treatment of superficial bladder cancer, where his computer-based simulations suggested that treatment responses for the widely used drug mitomycin C could be increased from 20 to 40%. An international multi-center randomized trial confirmed his estimates and established the current standard treatment protocol for this drug. He is further interested in regional delivery to prostatic, pancreatic and intraperitoneal tumors.
Dr. Wientjes is a fellow of the AAPS and AAAS, and has served as member and chair of several advisory committees to the National Institutes of Health.

Xiang-Qun (Sean) Xie, M.D., Ph.D., EMBA 

Xiang-Qun (Sean) Xie, Ph.D., is an associate dean for research innovation at the School of Pharmacy and professor of pharmaceutical sciences in the Drug Discovery Institute at the University of Pittsburgh. He serves as a member of the United States Food and Drug Administration’s (FDA) SCIENCE Board (the FDA’s highest advisory committee), and a charter member of the National Institutes of Health (NIH) BPNS Study Section. He is a recipient of 2014 AAPS Outstanding Research Achievement Award (the most prestigious award in pharmaceutical sciences). Sean Xie is principal investigator (PI) of an integrated research lab of CompuCore, BioCore, and ChemCore (www.CBLigand.org/XieLab), founding director of Computational Chemical Genomics Screening (CCGS) Center (www.CBLigand.org/CCGS), and director/PI of NIH-funded National Center of Excellence for Computational Chemogenomics Drug Abuse Research (www.CDARCenter.org). He also holds joint faculty positions at the Department of Computational Biology and Department of Structural Biology, and at the Pitt Cancer Institute MT/DD Program. He serves as an oversea expert for the Chinese Natural Science Foundation, ad hoc reviewer for Netherlands Organization for Scientific Research (NWO) Council for Chemical Sciences (CW), MCMB Foundation for MRC United Kingdom, and the Wellcome Trust Fund, Sir Henry Wellcome Fellowship, London, UK.
He is an invited guest editor for The AAPS Journal, an editorial board member of the American Journal of Molecular Biology, and an associate editor and editorial board member of BMC Pharmacology and Toxicology. He also holds/held an honorary professorship in top institutes and colleges of pharmacy in China, including the Chinese Academy of Medical Sciences & Peking Union Medical College; Stem Cell Medical Center, CAMS Tianjin Institute of Hematology; Fudan University; Shanghai Jiaotong University; and Zhejiang University. Xie was co-PI/core director of the NIH-funded Pittsburgh Center for Chemical Methodologies & Library Development (UPCMLD) and NCI/SAIC-funded University of Pittsburgh Center for Diversity Chemistry (UP-CDC). He was co-PI of the Pittsburgh Molecular Library Screening Center (PMLSC), which was funded by the NIH Roadmap Initiative.
Xie received his pharmacy M.D. degree in 1982 from the Second Military Medical University in Shanghai China; his Ph.D. in medicinal chemistry from the School of Pharmacy, University of Connecticut, 1993; and followed with biophysics postdoctoral training at MIT Francis Bitter National Magnet Laboratory/UCONN. In addition, he received an Executive M.B.A. degree in 2003. In 2011, he also received the Shared Leadership Cohort Development Experience Workshop Training by JPorcari & Associates, LLC.
Before he joined Pitt, he was a founding director of the Pharmacoinformatics Research Center at the College of Pharmacy at the University of Houston, Texas. He held several joint faculty positions at the Institute for Molecular Design (MDL), Texas Learning Computing Center (TLCC), and the Keck Center for Computational & Structural Biology, served as an advisory committee member for the NIH Pharmacoinformatics Training Program at Houston Gulf Coast Consortium (GCC), and was a director of the Chemistry Coordinating Unit for GCC-Chemical Genomics Screening Center. Prior to UH, Xie was a director of the IMS NMR Lab and a joint faculty of the School of Pharmacy at the University of Connecticut for over 10 years, where he received multiple NIH grants and pharma support, including Pfizer, Boston Scientific companies, etc. He was an invited International Assessment Panelist for Fudan University College of Pharmacy, a member of the board of directors of the Chinese Association of Professionals in Science and Technology (CAPST), and a chair of the CAPST-Biomedical & Pharmaceutical Society. He was keynote speaker and session chair/organizing committee for several international medicinal chemistry and drug design conferences/meetings.

Bret Ulery, Ph.D., early career member 

P_A67933_Bret Ulery-Head Shot_95x120pxpx
Bret Ulery is the Principal Investigator of the Biomodulatory Materials Engineering Laboratory, the Director of the Missouri Environmental Assistance Center, the Director of Chemical Engineering Graduate Studies, and an Assistant Professor of Biomedical, Biological, and Chemical Engineering at the University of Missouri. After earning a B.S.E. in Chemical Engineering and a B.S. in Biochemistry from the University of Iowa in 2006, he conducted graduate research with Dr. Balaji Narasimhan at Iowa State University and received his Ph.D. in Chemical Engineering with a Graduate Minor in Immunobiology in 2010. Following completion of his doctoral studies, he spent four years as a postdoctoral researcher first working in Dr. Cato Laurencin’s research group at the Institute for Regenerative Engineering at the University of Connecticut Health Center and then in Dr. Matt Tirrell’s group at the Institute for Molecular Engineering at the University of Chicago.

Masato Yasuhara, Ph.D. 

Dr. Yasuhara is a Professor of Pharmacokinetics and Pharmacodynamics at Tokyo Medical and Dental University. He received a B.S. in Pharmacy (1974) and a Ph.D. in Pharmaceutics (1979) from Kyoto University, Japan. He served as an Assistant Professor of Department of Pharmacy at Kyoto University Hospital, Faculty of Medicine, Kyoto University from 1979-1985. He was a postdoctoral research fellow at the State University of New York at Buffalo from 1985-1987. He rejoined the Department of Pharmacy at Kyoto University Hospital as an Assistant Professor in 1987, and promoted to Lecturer in 1988 and to Associate Professor in 1990. In 1995, Dr. Yasuhara joined the Faculty of Medicine, Tokyo Medical and Dental University, as a Full Professor. He served the Director of the Department of Pharmacy at the Medical University Hospital from 1995-2014.
His research focuses on the kinetics of drug action in disease states and on the therapeutic drug monitoring and clinical pharmacokinetics. He has published over 100 research papers. He is a recipient of The Japanese Society for the Study of Xenobiotics Award for Young Scientists (1992), The Academy of Pharmaceutical Science and Technology, Japan Award (2012) and The Japanese Society of Pharmaceutical Health Care and Sciences Achievement Award (2015).
He is a member of the American Association of Pharmaceutical Scientists (AAPS) and the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He served as President of The Japanese Society of Pharmaceutical Health Care and Sciences from 2010-2014. Currently, he is a member of Science Council of Japan and serves as the Executive Director of Liaison Association of Medical Schools’ Ethics Committees in Japan.